Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ESSA Pharma Inc EPIX

Healthcare Biotechnology
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a... see more

Recent & Breaking News (NDAQ:EPIX)

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

PR Newswire 10 days ago

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

PR Newswire March 7, 2024

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

PR Newswire February 13, 2024

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

PR Newswire February 6, 2024

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

PR Newswire January 25, 2024

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

PR Newswire December 12, 2023

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

PR Newswire November 21, 2023

ESSA Pharma to Present at the Jefferies London Healthcare Conference

PR Newswire November 8, 2023

ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement

PR Newswire November 6, 2023

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

PR Newswire October 26, 2023

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress

PR Newswire October 21, 2023

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

PR Newswire September 18, 2023

ESSA Pharma Insiders Establish Automatic Securities Disposition Plans

PR Newswire August 31, 2023

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023

PR Newswire August 8, 2023

ESSA Pharma Appoints Lauren Merendino to its Board of Directors

PR Newswire June 6, 2023

ESSA Pharma to Present at 2023 Jefferies Healthcare Conference

PR Newswire June 1, 2023

ESSA Pharma to Present at JMP Securities Life Sciences Conference

PR Newswire May 11, 2023

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023

PR Newswire May 9, 2023

ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

PR Newswire April 18, 2023

ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer

PR Newswire April 12, 2023